Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial

A Carpio,1,2 E A Kelvin,2,3 E Bagiella,4 D Leslie,5,6 P Leon,7 H Andrews,3,4 W A Hauser,2,8 the Ecuadorian Neurocysticercosis Group

ABSTRACT

Aim: The aim of this trial was to evaluate the effects of albendazole (ALB) on cyst disappearance, reduction of the number of cysts and seizure recurrence.

Methods: 178 patients with new onset symptoms due to active or transitional neurocysticercosis were randomly assigned to receive either 800 mg of ALB daily or placebo for 8 days. All patients also received prednisone. Imaging studies were done at baseline and at months 1, 6 and 12 of follow-up.

Results: Active cysts were identified in 59 of 88 people randomised to ALB and 57 of the 90 in the placebo arm. By 1 month, 31% were free of active cysts in the treatment group compared with 7% in the placebo group (p = 0.001). In addition, the ALB group had a greater reduction in the number of active cysts compared with the placebo group (p = 0.001). After 1 month following treatment there was no additional gain by treatment group in the disappearance or reduction in the number of active cysts. ALB treatment had little effect on cysts in the transitional or calcification stage. We found no difference between the ALB and placebo groups in symptoms during treatment or in seizure recurrence during the 12 months after treatment.

Conclusion: Albendazole plus symptomatic treatment leads to the disappearance of active cysts in 31% of patients compared with 7% of those with symptomatic treatment alone. This treatment effect occurs within the first 30 days after treatment.

Trial registration number: NCT00283699.

Neurocysticercosis (NC), the infection caused by the larval stage of the tapeworm Taenia solium, is the most frequently occurring parasitic disease affecting the human CNS.1 The disease is associated with clinical manifestations such as seizures, headache and focal neurological deficits.1,2 NC is a serious public health problem for most of the developing world as well as for developed countries with high immigration rates from endemic countries in Latin America, Asia and Africa.3 NC has been designated as an emerging infection by the US Centers for Disease Control.3–5

A number of studies have been published related to treatment for NC with antihelminthic drugs (AHD), such as praziquantel and albendazole (ALB).6–10 Although treatment should cause earlier degeneration of cysticerci and could therefore decrease the risk of persistent neurological symptoms,2 there are concerns that seizures and other neurological events can be triggered by the inflammatory reaction to treatment induced cysticercal degeneration.5 Frequently, spontaneous resolution of parenchymal cysticerci is observed on serial imaging studies.5 A systematic review of the literature stated that there is insufficient evidence to conclude that AHD treatment is associated with therapeutic benefit in NC and a recent meta-analysis of NC treatment concluded that there was evidence of only a modest effect of drug treatment in patients with NC.11 To date, there remains a debate over the value and safety of AHD therapy.12,13

This paper reports the results of a double blind, randomised, placebo controlled trial to evaluate the effects of ALB treatment on cyst disappearance, reduction in the number of cysts and seizure recurrence in patients with NC.

METHODS

Participants

Patients were recruited from six hospitals in Ecuador: three in Quito, two in Cuenca and one in Guayaquil. Approval for the study was granted by the Institutional Review Board of Columbia University, the Office for Human Research Protection (OHRP) of the National Institutes of Health in the USA, as well as the ethics committees at each of the participating hospitals.

Patients of any age or gender were eligible to participate if they had experienced new onset of symptoms associated with NC within 2 months prior to recruitment and had active and/or transitional NC cysts identified on axial CT or MRI of the brain. Non-inclusion criteria included having only calcifications, pregnancy, papilloedema, active tuberculosis, syphilis, ocular cysticercosis, active gastric ulcers or any progressive or life-threatening disorder. Patients who had received AHD during the year preceding presentation or who had received steroids within 30 days of presentation were also ineligible. Midway through the study, patients with ventricular shunt were excluded for safety concerns.

Diagnostic criteria for neurocysticercosis

A diagnosis of NC was made if a patient met any of the following criteria:13

1. One or more active parenchymal cysts: the CT scan shows circumscribed, rounded, hypodense areas without contrast enhancement. The MRI shows a CSF-like intensity signal on all sequences with no surrounding high signal. Both MRI and CT may show a high intensity or hyperdense 2–4 mm mural nodule depicting the scolex in the interior of the cyst.

2. One or more transition or degenerative parenchymal cysts: the CT scan shows annular contrast enhancement, surrounded by irregular
perilesional oedema; there is a diffuse hypodense area with irregular borders on non-contrast CT, or a small, hyperdense, nodule surrounded by oedema. On MRI, the fluid content is of higher signal than CSF on T1 and T2 weighted images. The cyst capsule exhibits of low signal on the T2 images, is surrounded by oedema and enhances on gadolinium enhanced T1 weighted images.

3. Any of the above descriptions associated with an extra-parenchymal location.

Interventions
For participants weighing more than 50 kg, active treatment consisted of 400 mg of ALB given orally every 12 h for 8 days. This dose has been used in other trials and longer duration of treatment does not seem to have any advantage. For participants weighing less than 50 kg (including children), a dose of 15 mg/kg/day for 8 days was prescribed, as suggested by the drug manufacturers. The study pharmacist prepackaged bottles of 32 active drug (200 mg ALB tablets) or 32 identical looking placebo tablets identified only by an assigned letter to maintain the blinding of study staff. The study nurse dispensed the drug in hospital and directly observed the patient taking the medication.

All patients received prednisone. Participants weighing 50 kg or more received 75 mg of prednisone daily for 8 days, then 50 mg/day for 1 week and finally 25 mg/day for 1 week. Participants weighing less than 50 kg were prescribed 1.5 mg/kg/day for 8 days, then 1 mg/kg/day for 1 week and finally 0.5 mg/kg/day for 1 week. Patients with newly occurring seizures were prescribed phenytoin at standard doses. Carbamazepine was substituted if phenytoin was contraindicated or if seizure control was not achieved with phenytoin.

At enrolment, patients were interviewed to collect information on demographics and symptoms. In addition, a study related brain CT or MRI with and without contrast was taken within 2 weeks of enrolment. During treatment, the study nurse monitored patients daily for adverse events, using a precoded symptom checklist. Information on symptoms was also collected at each follow-up visit in a similar manner. An independent safety monitoring committee was established to review the safety of all enrolled patients on an ongoing basis.

The research staff in Ecuador entered all data into a web based database using Scientific Web based Information Management Software (SBS Inc.), located on a server at Columbia University. The rate of data entry error was consistently found to be less than 2%.

CT and MRI images were posted to a secure website from which they were accessible for reading by two neuroradiologists, one in Ecuador and one in the USA. Follow-up images were of the same type (CT or MRI) as the baseline image in order to make comparisons. Each scan was read independently, without knowledge of treatment arm or results of prior scans. Information collected from each scan included number of cysts of each phase (active, transitional and inactive calcification) by brain location. The inter-rater reliability of the readings was fair.

Figure 1  Flow diagram of a multicentre trial comparing albendazole with placebo in patients with neurocysticercosis.

### Figure 1
Flow diagram of a multicentre trial comparing albendazole with placebo in patients with neurocysticercosis.
### Table 1 Characteristics of the patients at baseline

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Albenzole (n = 84)</th>
<th>Placebo (n = 90)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographic information</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (y) (mean (SE))</td>
<td>39.39 (17.79)</td>
<td>41.55 (16.80)</td>
</tr>
<tr>
<td>Children (&lt;18 y) (No (valid %))</td>
<td>8 (9.2)</td>
<td>7 (8.0)</td>
</tr>
<tr>
<td>Males (No (valid %))</td>
<td>51 (58.6)</td>
<td>46 (52.9)</td>
</tr>
<tr>
<td>Females (No (valid %))</td>
<td>36 (41.4)</td>
<td>41 (47.1)</td>
</tr>
<tr>
<td>Missing age and gender information (n)</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td><strong>Cyst phase and location</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active cysts (No (valid %))</td>
<td>59 (68.6)</td>
<td>57 (66.3)</td>
</tr>
<tr>
<td>Transitional (No (valid %))</td>
<td>49 (57.0)</td>
<td>54 (66.8)</td>
</tr>
<tr>
<td>Calcifications (No (valid %))</td>
<td>38 (44.2)</td>
<td>32 (37.2)</td>
</tr>
<tr>
<td>Parenchymal cysts (No (valid %))</td>
<td>74 (86.0)</td>
<td>74 (82.2)</td>
</tr>
<tr>
<td>Active parenchymal cysts</td>
<td>45 (52.3)</td>
<td>39 (45.3)</td>
</tr>
<tr>
<td>Transitional parenchymal cysts</td>
<td>40 (46.5)</td>
<td>52 (60.5)</td>
</tr>
<tr>
<td>Calcified parenchymal cysts</td>
<td>35 (40.7)</td>
<td>31 (36.0)</td>
</tr>
<tr>
<td>Extraparenchymal cysts (No (valid %))</td>
<td>35 (40.7)</td>
<td>42 (48.8)</td>
</tr>
<tr>
<td>Active extraparenchymal cysts</td>
<td>28 (32.6)</td>
<td>30 (34.9)</td>
</tr>
<tr>
<td>Transitional extraparenchymal cysts</td>
<td>11 (12.8)</td>
<td>13 (15.1)</td>
</tr>
<tr>
<td>Calcified extraparenchymal cysts</td>
<td>7 (8.1)</td>
<td>7 (8.1)</td>
</tr>
<tr>
<td>Missing baseline scan (n)</td>
<td>2</td>
<td>4</td>
</tr>
</tbody>
</table>

*Categories are not mutually exclusive; patients may have had cysts of more than one type and in more than one location and may have experienced multiple symptoms.

Sample size and randomisation

Sample size was determined for the primary outcome (the proportion of patients free of active cysts at 6 months). A sample size of 270 patients was estimated to be necessary to have 90% power to detect a response rate difference of 18% or more between the two groups.

Patients were allocated to treatment group according to a stratified block randomisation scheme. Two strata were considered: centre (six centres) and location of the cyst (parenchymal vs extraparenchymal). Permuted blocks of size 4 and 6 were used to balance the treatment allocation within each stratum. The randomisation lists were kept in electronic form on a computer accessible only to the statistician. All other research staff were blinded to the treatment arm.

Statistical methods

All analyses were performed according to an intent to treat principle. Thus all patients randomised were included in the group to which they were initially assigned, regardless of adherence. All tests were conducted at the 0.05 two tailed significance level.

The primary outcome measure was disappearance of active cysts by 12 months of follow-up, evaluated through serial imaging studies. The chi-square test was used to compare the proportion of patients free of active cysts at 12 months. We also explored active cyst disappearance before 12 months and the possible interaction of drug treatment with the patient’s weight (as a continuous variable and as a categorical variable defined as ≤60 kg) in predicting active cyst disappearance using both stratified analysis and logistic regression.

Secondary outcomes included disappearance of transitional or calcified cysts at 1, 6 and 12 months, change in number of cysts in a specific phase, time to seizure recurrence and adverse events. For examining secondary outcomes, we used the Wilcoxon rank sum test to look at the change in the number of cysts between follow-up images. Kaplan–Meier curves and the log rank test were used to estimate time to seizure recurrence in the two treatment groups\(^a\); the chi-square or Fisher’s exact test was used to evaluate differences in potential adverse events during treatment and for the first month following treatment.

Follow-up

After treatment completion, patients were seen at 2 weeks, 1 month and every 3 months thereafter. Repeat scans were performed at 1 month, 6 months and 1 year after study entry.

RESULTS

Participants

Between February 2001 and February 2003, 178 patients with NC agreed to participate in the study; 88 patients were randomised to the ALB group and 90 to the placebo group (fig 1). Follow-up continued until February 2005.

Baseline data for all randomised patients is provided in table 1 by treatment group. Age range was 5–82 years (mean 59.4 years). Only 15 (9%) of the patients were less than 18 years old. Fifty-six per cent of the patients were men. After taking into account early withdrawals (eight patients withdrew after randomisation but before taking study medication), there were 84 cases in the active treatment arm and 86 cases in the placebo treatment arm (fig 1). Of the 107 patients with new onset seizure as a symptom at baseline, 51 (48%) were randomised to active treatment and 56 (52%) were randomised to receive placebo. Patients randomised to ALB had a greater number of calcifications at baseline (\(p = 0.018\)), but the frequency of lesions (active and transitional) and their location (parenchymal and extraparenchymal) were similar in the two treatment groups. Seventy-seven patients in each arm completed the entire 2 year follow-up period (fig 1).

Outcomes

Freedom from cysts

Active cysts were identified in 59 (69%) of the 86 people randomised to ALB and 57 (66%) of the 86 people in the placebo arm (table 2). By 12 months following treatment, 38% (20/53) of those with 12 month scans were free of active cysts in the treatment group compared with 20% (10/50) in the placebo group (\(p = 0.048\)). This difference in cyst disappearance by treatment was greatest at 1 month of follow-up, with 31% (18/58) of those in the ALB group being free of active cysts at month 1 of follow-up compared with 7% (4/53) of those in the placebo group (\(p = 0.001\)). Of those patients followed and scanned at 6 months, 38% (19/51) were free of active cysts in the treatment arm compared with 12% (6/50) in the placebo group (\(p = 0.006\)). A similar trend was seen when looking at active parenchymal and extraparenchymal cysts separately, but the association was not statistically significant for extraparenchymal cysts (table 2). There was no significant interaction between the drug and the participant’s weight in predicting the disappearance of active cysts.
Transitional cysts were identified in 49 (57%) of the 86 people randomised to ALB and in 54 (65%) of the 86 people in the placebo arm (table 2). By 1 month following treatment, 27% (13/47) of those with 1 month scans were free of transitional cysts in the treatment group compared with 23% (12/52) in the placebo group (p = 0.600). Of those patients followed and scanned at 6 months, 52% (22/42) were free of transitional cysts in the treatment arm compared with 39% (19/49) in the placebo group (p = 0.194). After 1 year of follow-up, 55% (23/42) of those in the treatment arm were free of transitional cysts compared with 23% (12/52) in the placebo arm (table 2). By 1 month following treatment, 27% (13/47) of those with 1 month scans were free of transitional cysts compared with 23% (12/52) in the placebo arm (p = 0.600). Of those patients followed and scanned at 6 months, 52% (22/42) were free of transitional cysts in the treatment arm compared with 39% (19/49) in the placebo group (p = 0.194). After 1 year of follow-up, 55% (23/42) of those in the treatment arm were free of transitional cysts compared with 23% (12/52) in the placebo arm (table 2). There was also no significant difference in the disappearance of transitional cysts by drug treatment in the subanalyses by brain location (parenchymal or extraparenchymal) (table 2).

### Seizure freedom

At baseline, 107 patients reported new onset of seizure. Of these, 51 (48%) were randomised to the ALB group and 56 (52%) to the placebo group. Using Kaplan–Meier survival analysis, the proportion of patients with seizure at baseline who were seizure free at 12 months of follow-up was 0.62 in the ALB group and 0.52 in the placebo group (fig 2). The mean time seizure free was 8.86 months in the ALB group versus 7.67 months in the placebo group; this difference was not statistically significant (p = 0.274). Findings were similar to those with only parenchymal cysts (p = 0.518) and those with any extraparenchymal cysts (with or without parenchymal cysts) (p = 0.998). It was not possible to evaluate seizure outcome for those with only extraparenchymal cysts because the number with seizures at baseline was small (four patients).

### Possible adverse events

The three most common symptoms reported during treatment and the first month following treatment were headache,
seizures and stomach problems (table 3). During the 8 days of treatment, three patients developed intracranial hypertension, all in the placebo group (table 3).

During the 2 year study period, seven people died, all but one due to cysticercosis. Two of the deaths occurred in the treatment group and five in the placebo group (fig 1). This difference was not statistically significant (Fisher’s exact test \( p = 0.213 \)). All but one of the deceased patients presented with the extraparenchymal form of NC, and four of the six had been shunted more than 1 year prior to study enrolment. Repeat shunting was performed in four patients with generally poor outcome. Shunting of NC patients is generally associated with a high shunt failure rate\(^{18,20}\) and high mortality.\(^{19,20}\)

**DISCUSSION**

Our primary analysis of active cyst disappearance by 12 months revealed a clear advantage for the ALB group compared with placebo, and the effect occurred within the first 30 days following initiation of treatment. There seems to be no additional advantage in the treatment group compared with placebo after this time. The reduction in the number of active cysts was also most pronounced at 1 month. Nonetheless, about 70% of people are not rendered free of active cysts with this first course of therapy. These results are similar to those reported by Garcia and colleagues.\(^{5}\) At 6 months after treatment, active cysts disappeared in 38% of patients receiving ALB plus steroids compared with 15% of patients receiving placebo alone. We also confirm previous reports regarding the lack of effectiveness of ALB treatment on transitional or degenerative cysts.\(^{21,25}\)

About half of the people with seizures at baseline remained seizure free at 1 year following initiation of treatment, and there was no significant effect of treatment with ALB on this outcome. This finding is similar to that obtained in our previous trial,\(^{26}\) two observational studies\(^{27,28}\) and two trials involving paediatric patients.\(^{29,29}\) However, several studies have found a significant reduction in seizures in patients treated with ALB, including two clinical trials with children,\(^{31,30}\) and a meta-analysis.\(^{31}\) A recent trial in adult patients did not find a reduction in the number of seizures overall, but did report a significant reduction in the number of generalised seizures in patients treated with ALB and steroids compared with those treated with only placebo.\(^{5}\) Thus the findings regarding the influence of ALB on seizure recurrence are inconsistent. However, there is no indication that ALB treatment increases the risk of seizures or any other adverse event. Symptoms during treatment and for the first month following treatment were similar in the ALB and placebo groups.

An important question that remains is the effect of ALB on extraparenchymal cysts. The association of treatment with the disappearance of active extraparenchymal cysts was not significant, although there was the suggestion of a trend. We did find a significant reduction in the number of active extraparenchymal cysts in the ALB group compared with the placebo group between baseline and month 1. This difference in the results by outcome (disappearance versus number of active cysts) may be due to a lack of statistical power to address cyst disappearance.

If the objective of treatment is to eradicate active cysts, it would appear that a single course of therapy with ALB (the usual practice) provides benefit over placebo in only 24% of patients. Since 69% of patients receiving ALB continue to demonstrate active cysts, new drugs or different treatment regimens need to be developed for this majority of patients with NC. Our finding that not all encysted parasites die after a single course of antiparasitic treatment was also described in a recent literature review.\(^{21}\) Treatment options to be explored may include a higher initial dose of drug, concomitant or subsequent treatment with an AHD that has a different mode of action, such as praziquantel, or a repeat course of ALB or of another AHD in those with persistent active cysts at 1 month. We also need studies to explore reasons for the heterogeneous effect of ALB to guide the development of treatment strategies for the large proportion of patients who do not seem to benefit from ALB.

**Acknowledgements:** We are indebted to Drs Eduardo Castro, Gastón Rodríguez, Iván Reinoso, Víctor Paredes and Carlos Barrionuevo of the “Carlos Andrade Marín” Hospital of Quito, Ecuador, for support in patient care, and to Dr Franklin Santillán of the Social Security Hospital of Cuenca, Ecuador, for patient referrals. Other members of the Neurocysticercosis Clinical Trial Group who collaborated in this study include: Karina Quinde, Research Assistant; Ana Montenegro, Research Social Worker; Alicia Vaso, Research Nurse; Mey Dibregon, Research Nurse; Luis Vilalta, Accountant; Nora Hernandez, MD, Project Coordinator; Mary Angie Garcia, Research Assistant; Nora Hernandez, MD, Project Coordinator; Mary Angie Garcia, Research Assistant. The authors of this manuscript participated in the study design and implementation, as well as in the data analysis and/or manuscript preparation.

**Funding:** This study was supported by NINDS grant #R01-NS39403; Glaxo/SKB and Acromax Co supplied active drug and placebo.

**Competing interests:** None.
Ethics approval: Approval for the study was granted by the Institutional Review Board of Columbia University, the Office for Human Research Protection (OHRP) of the National Institutes of Health in the USA, as well as the ethics committees at each of the participating hospitals.

The Ecuadorian Neurocysticercosis Group: Noemi Lisanti, (“Comprehensive Epilepsy Center”, Cuenca), Rafael Aguirre, (“Teodoro Maldonado” Hospital, Guayaquil), Marcos Schantz P., (“Eugenio Espejo” Hospital, Quito), Jorge Pesantes, Jorge Moncayo, (“Carlos Andrade Marin” Hospital, Quito), Rafael Aguirre, (“Teodoro Maldonado” Hospital, Guayaquil), Marcos Schantz P., (“Eugenio Espejo” Hospital, Quito) and Marcelo Roman, (“Baca Ortiz” Hospital, Quito). 

REFERENCES